ERBB2 and breast cancer: Despite the use of the aforementioned HER2-targeted therapies, patients with advanced HER2-positive breast cancer still develop resistance to the best combination regimens (e.g., trastuzumab, pertuzumab, and docetaxel) and progression-free survival is still only 18.5 months [9].